{
  "id": 12451144,
  "title": "US small/mid-cap pharma outlook: top picks from a 15-stock screen",
  "url": "https://urgent.news/2026/10/06/us-small-mid-cap-pharma-outlook-top-picks-from-a-15-stock-screen",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-06T19:28:42.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/us-smallmidcap-pharma-outlook-top-picks-from-a-15stock-screen-93CH-4935116"
  },
  "original_language": "en",
  "account": "Investing.com reports on a US small/mid-cap pharma outlook, highlighting a 15-stock screen. The sector is driven by strong stock momentum rather than sector-wide growth. Fifteen US pharma companies with market caps between $300M and $10B were considered, and 15 were identified. Harmony Biosciences (HRMY) emerges as the top pick, boasting an 'Excellent' health label, a 24.3% revenue growth rate, a 7.4x forward P/E ratio, and an analyst upside of 20.8%. Despite its 3-month return of 6.4%, it has not grown as rapidly as competitors like Eton (ETON), which has a 47.6% return. HRMY's concentrated product exposure and upcoming patent expiration are factors to consider, but the data-driven selection is not a buy recommendation. Indivior (INDV) follows as the runner-up on valuation. This summary was generated with AI assistance and reviewed by an editor.",
  "summary": null,
  "key_points": [
    "US small/mid-cap pharma sector driven by strong stock momentum",
    "Harmony Biosciences (HRMY) top pick with 20.8% analyst upside",
    "Indivior (INDV) runner-up on valuation despite patent expiration concerns"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}